Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: Results from a population-based retrospective cohort study

Addiction

Volumn 107, Issue 9, 2012, Pages 1621-1629

  Nosyk, Bohdan ^a,b   Sun, Huiying ^c   Evans, Elizabeth ^b   Marsh, David C ^d   Anglin, M Douglas ^b   Hser, Yih Ing ^b   Anis, Aslam H ^c,e  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CENTRE FOR HEALTH EVALUATION AND OUTCOME SCIENCES   (Canada)

^d NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Methadone detoxification; Methadone maintenance treatment; Methadone tapering; Opioid dependence; Opioid substitution treatment

Indexed keywords

METHADONE; NARCOTIC AGENT;

ADULT; AGED; ARTICLE; CANADA; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; BRITISH COLUMBIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; METHADONE; MIDDLE AGED; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84864771161     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2012.03870.x     Document Type: Article

References (42)

1. McLellan A. T., Lewis D. C., O'Brien C. P., Kleber H. D. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000; 284: 1689-95.
2. National consensus development panel on effective medical treatment of opiate addiction. Effective medical treatment of opiate addiction. JAMA 1998; 280: 1936-43.
3. Amato L., Davoli M., Perucci C. A., Ferri M., Faggiano F., Mattick R. P. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 2005; 28: 321-9.
4. Mattick R., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008; 2: CD002207.
5. Burns L., Randall D., Hall W. D., Law M., Butler T., Bell J. etal. Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention. Addiction 2009; 104: 1363-72.
6. Nosyk B., Guh D., Sun H., Oviedo-Joekes E., Marsh D. C., Brissette S. etal. Health related quality of life trajectories of patients in opioid substitution treatment. Drug Alcohol Depend 2011; 118: 259-64.
7. Degenhardt L., Bucello C., Mathers B., Briegleb C., Ali H., Hickman M. etal. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction 2011; 106: 32-51.
8. Sees K. L., Delucchi K. L., Masson C., Rosen A., Clark H. W., Robillard H. etal. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA 2000; 283: 1303-10.
9. Amato L., Davoli M., Minozzi S., Ali R., Ferri M. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev 2005; 3: CD003409.
10. Amato L., Minozzi S., Davoli M., Vecchi S. Psychosocial and pharmacological treatment versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev 2011; 9: CD005031.
11. Bammer G., Battisson L., Ward J., Wilson S. The impact on retention of expansion of an Australian public methadone program. Drug Alcohol Depend 2000; 58: 173-80.
12. Calsyn D. A., Malcy J. A., Saxon A. J. Slow tapering from methadone maintenance in a program encouraging indefinite maintenance. J Subst Abuse Treat 2006; 30: 159-63.
13. Cushman P. Jr. Ten years of methadone maintenance treatment: some clinical observations. Am J Drug Alcohol Abuse 1977; 4: 543-53.
14. Dennis M., Scott C. K. Managing addiction as a chronic condition. Addict Sci Clin Pract 2007; 4: 45-55.
15. Gearing F. R. Methadone maintenance treatment. Five years later-where are they now? Am J Public Health 1974; 64: 44-50.
16. Termorshuizen F., Krol A., Prins M., Geskus R., van den Brink W., van Ameijden E. J. Prediction of relapse to frequent heroin use and the role of methadone prescription: an analysis of the Amsterdam Cohort Study among drug users. Drug Alcohol Depend 2005; 79: 231-40.
17. Substance Abuse and Mental Health Services Administration (SAMHSA), Office of Applied Studies. Treatment Episode Data Set (TEDS). Highlights-2006. National Admissions to Substance Abuse Treatment Services, DASIS Series: S-40, DHHS Publication no. (SMA) 08-4313. Rockville, MD: SAMHSA; 2008.
18. Nosyk B., Marsh D. C., Sun H., Schechter M. T., Anis A. H. Trends in methadone maintenance treatment participation, retention and compliance to dosing guidelines in British Columbia, Canada: 1996-2006. J Subst Abuse Treat 2010; 39: 22-31.
19. Eklund C., Melin L., Hiltunen A. J., Borg S. Detoxification from methadone maintenance treatment in Sweden: long-term outcome and effects on quality of life and life situation. Int J Addict 1994; 29: 627-45.
20. ® at ).
21. College of Physicians and Surgeons of British Columbia. Methadone Maintenance Handbook 2012. Available at: (accessed 23 February 2012) (archived by WebCite® at ).
22. Centre for Addiction and Mental Health. Methadone Maintenance Treatment: Client Handbook 2008. Available at: (accessed 23 February 2012) (archived by WebCite® at ).
23. College of Physicians and Surgeons of Ontario. Methadone Maintenance Treatment Program Standards and Clinical Guidelines. February, 2011. Available at: (accessed 23 February 2012) (archived by WebCite® at ).
24. Senay E. C., Dorus W., Goldberg F., Thornton W. Withdrawal from methadone maintenance. Rate of withdrawal and expectation. Arch Gen Psychiatry 1977; 34: 361-7.
25. Latowsky M. Improving detoxification outcomes from methadone maintenance treatment: the interrelationships of affective states and protracted withdrawal. J Psychoact Drugs 1996; 28: 251-7.
26. Magura S., Rosenblum A. Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored. Mt Sinai J Med 2001; 68: 62-74.
27. Milby J. B. Methadone maintenance to abstinence. How many make it? J Nerv Ment Dis 1988; 176: 409-22.
28. Nosyk B., MacNab Y. C., Sun H., Fischer B., Marsh D. C., Schechter M. T. etal. Proportional hazards frailty models for recurrent methadone maintenance treatment. Am J Epidemiol 2009; 170: 783-92.
29. Caplehorn J. R. M., Dalton M. S. Y. N., Cluff M. C., Petrenas A. M. Retention in methadone maintenance and heroin addicts' risk of death. Addiction 1994; 89: 203-7.
30. Payte J. T., Khuri E. T. Principles of methadone dose determination. In: Parrino M. W., editor. State Methadone Treatment Guidelines: Treatment Improvement Series #1. [Publication no. SMA 93-1991]. Rockville, MD: US Department of Health and Human Services; 1991, p. 47-58.
31. Population Data BC: BC PharmaNet database, BC Ministry of Health Discharge Abstract Database, Vital Statistics database 2012. Available at: (accessed 23 February 2012) (archived by WebCite® at ).
32. Laudet A. B., White W. L. Recovery capital as prospective predictor of sustained recovery, life satisfaction and stress among former poly-substance users. Subst Use Misuse 2008; 43: 27-54.
33. Laudet A. B. What does recovery mean to you? Lessons from the recovery experience for research and practice. J Subst Abuse Treat 2007; 33: 243-56.
34. Schneeweiss S., Seeger J. D., Maclure M., Wang P. S., Avorn J., Glynn R. J. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001; 154: 854-64.
35. Hubbard R. L., Craddock S. G., Anderson J. Overview of 5-year follow-up outcomes in the drug abuse treatment outcome studies (DATOS). J Subst Abuse Treat 2003; 25: 125-34.
36. Zhang Z., Friedmann P. D., Gerstein D. R. Does retention matter? Treatment duration and improvement in drug use. Addiction 2003; 98: 673-84.
37. Dolan K. A., Shearer J., White B., Zhou J., Kaldor J., Wodak A. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction 2005; 100: 820-8.
38. Darke S. The effectiveness of methadone maintenance treatment 3: moderators of treatment outcome. In: Ward J., Mattick R. P., Hall W., editors. Methadone Maintenance Treatment and Other Opioid Replacement Therapies. Amsterdam: Overseas Publishers Association, Harwood Academic Publishers; 1998, p. 75-89.
39. Faggiano F., Vigna-Taglianti F., Versino E., Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev 2003; 3: CD002208.
40. Oppenheimer E., Stimson G. V., Thorley A. Seven-year follow-up of heroin addicts: abstinence and continued use compared. BMJ 1979; 2: 627-30.
41. Capone C. T., Haggerty E. L., Acer K., Melchionda R., Holley E., Adams H. etal. Client variables associated with selection and outcome in a methadone tapering program. Int J Addict 1994; 29: 387-94.
42. Fewell Z., Smith D., Sterne J. A. C. The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study. Am J Epidemiol 2007; 166: 646-55.